Nov. 19-22, the board meeting of GAVI Alliance was held in Phnom Penh, Cambodia. Delegate of Sinopharm CNBG was invited to attend the meeting as observer.
A proposal of funding procurement of Japanese Encephalitis vaccine (live) was approved on the board meeting, which means, since 2014, those countries and regions in which JE widely spread may apply for financial aid to purchase JE vaccine (live) for immunization campaign from GAVI. It is a milestone in the history of JE vaccine (live) project. According to GAVI’s budget, the financial support for JE vaccine (live) project between 2015 and 2020 will be about US $105m, and the expenses for implementation and routine immunization will be borne by the aided countries themselves.
The JE epidemic countries funded by the GAVI include Nepal, Bangladesh, Pakistan, Vietnam, Cambodia, Laos, North Korea, East Timor and Papua New Guinea, etc.. Among them, Cambodia and Laos are likely to be the first two countries for applying the aid.
Just in Oct. 9, 2013, the JE vaccine (live) produced by Sinopharm CDIBP passed the WHO prequalification. It is the solitary case that GAVI approved to fund the procurement of a vaccine within only 2 months after prequalification, shows the international community’s high expectation on this vaccine.
The GAVI Alliance (“Global Alliance for Vaccines and Immunisation”), established in 1999, is a public-private global health partnership committed to promote the health and immunization worldwide by cooperating with governments and non-governmental organizations though providing technological and financial support. Currently, GAVI funds to purchase vaccines fighting hepatitis B, influenza and yellow fever. The associate members of GAVI include the developing countries and the donor governments, WHO, UNICEF, the World Bank, industrial and developing countries vaccine industry, Bill and Melinda Gates Foundation, NGOs and scientific research and health technology research institute. [Reported by Sinopharm CNBG]